Skip to main content
Retour
Watch Compare

Estrella Immunopharma, Inc.

Qualité des données : 83%
Également cotée sous ESLAW Nasdaq
ESLA
Nasdaq Manufacturing Chemicals
1,84 €
▼ 0,01 € (-0,54%)
Cap. Boursière: 78,08 M
Prix
1,83 €
Cap. Boursière
78,08 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -1,79 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,15
Interest CoverageN/A

Valorisation

PE (TTM)
-5,98
En dessous de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -6,0 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

2 analystes
Buy
Actuel
1,84 €
+443.5%
Objectif
10,00 €
8,00 €
10,00 €
12,00 €
Prévisions
P/E Prévisionnel -4,72
BPA Prévisionnel -0,39 €
CA Est. 0,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,39 €
-0,46 € – -0,32 €
 0,0 2
FY2026 -0,39 €
-0,39 € – -0,39 €
 0,0 1

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,07 € -0,01 € +85,7%
Q32025 -0,07 € -0,13 € -85,7%
Q22025 -0,12 € -0,15 € -25,0%
Q12025 -0,12 € N/A —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -13,06 M
ROE N/A ROA -401,70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1,79 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,15
Interest Coverage N/A Asset Turnover N/A
Working Capital -11,34 M Tangible Book Value -9,84 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,98 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2,29%
Market Cap 78,08 M Enterprise Value 76,45 M
Per Share
EPS (Diluted TTM) -0,35 Revenue / Share N/A
FCF / Share -0,04 OCF / Share -0,04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 13,67%
SBC-Adj. FCF -2,26 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Revenue — — — —
Net Income -13,06 M -4,43 M -247 718,0 -996 104,0
EPS (Diluted) -0,35 -0,12 — —
Gross Profit — — — —
Operating Income -13,06 M -4,43 M -249 146,0 -1,57 M
EBITDA — — — —
R&D Expenses 10,25 M 2,86 M — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 838,0 63,0 0,0 80 648,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Total Assets 3,18 M 3,14 M 45,80 M 9,72 M
Total Liabilities 13,54 M 3,00 M 1,62 M 2,65 M
Shareholders' Equity -10,37 M 143 731,0 -1,01 M -2,26 M
Total Debt — — — —
Cash & Equivalents 1,38 M 916 916,0 478 868,0 40 802,0
Current Assets 1,68 M 1,64 M 616 034,0 52 427,0
Current Liabilities 13,54 M 3,00 M 73 154,0 1,07 M